Moderna's Covid vaccine highly successful in trial

Covid-19 vaccine  / Photo illustration: Dado Ruvic illiustration Reuters , Reuters
Covid-19 vaccine / Photo illustration: Dado Ruvic illiustration Reuters , Reuters

Israel has agreements with both Moderna and Pfizer for the supply of vaccines against the coronavirus.

Following the surprise announcement by Pfizer last week of clinical trial results showing 90% efficacy for its vaccine against Covid-19, another US company, Moderna, has now published similar interim results for the vaccine that is has produced using the same technology.

The results are from 30,000 volunteers. 95 of them became ill with the coronavirus, but when the envelopes were opened to find out how many of them were from the trial group and how many from the control group, it turned out that 90 received the dummy vaccination, and only five received the real vaccine, indicating that he vaccine is highly effective at preventing the disease.

The fact that the trials of both Pfizer and Moderna were successful reduces the chances of statistical error. Like Pfizer, Moderna too will have to wait a few weeks for the safety results of all the volunteers in order to apply to the US Food and Drug Administration for approval.

Israel has agreements with both companies, which means that the chances of Israel being able to immunize a substantial proportion of its population over the next year have risen substantially, assuming that there are no surprises in the full trial results or in in the safety results, or breakdowns in production or transport.

Moderna has started setting up its production and transport system, and although it is less experienced than Pfizer in those areas, it has an advantage in that its vaccine requires less deep refrigeration during transportation than that of Pfizer.

Moderna's share price is up by more than 14% in before hours trading in New York.

Published by Globes, Israel business news - en.globes.co.il - on November 16, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Covid-19 vaccine  / Photo illustration: Dado Ruvic illiustration Reuters , Reuters
Covid-19 vaccine / Photo illustration: Dado Ruvic illiustration Reuters , Reuters
Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Isracard shareholders approve acquisition by Delek

For the deal to go through, approval is now needed from the Supervisor of Banks and the Israel Competition Authority.

Air Canada Photo: Shutterstock Air Canada to resume Israel flights in June

The Canadian airline will resume Toronto-Tel Aviv flights on June 8 and Montreal-Tel Aviv flights in August.

NICE CEO Scott Russell credit: SAP NICE Systems falls sharply on disappointing 2025 guidance

NICE sees $693-703 million revenue in the first quarter of 2025, up 6% from the corresponding quarter of 2024, with non-GAAP earnings per share of $2.78-2.88 - 3.8% below the analysts' consensus for revenue and 2.4% below for profit.

Tel Aviv credit: Shutterstock Urban renewal plan approved in heart of Tel Aviv

The plan for the Hahashmal neighborhood opposite the Old Central Bus Station includes a 30-floor tower.

Smartshooter credit: Smartshooter Germany buys Kibbutz Yagur's Smartshooter AI sights

The product family includes systems mounted on personal rifles, remotely controlled systems, and systems carried by vehicles, robots, and even drones.

Chinese ship in Suez Canal credit: Suez Canal Authority Direct shipping to Israel could resume soon

The first shipments of vehicles are likely to reach Israel via the Suez Canal in the coming months.

Sde Dov credit: Guy Yehieli Sde Dov land prices down over 40%

Four huge tenders for almost 4,000 homes, which have been successfully marketed in the north Tel Aviv district, reflect prices over 40% lower than in 2022.

Wix president Nir Zohar credit: Alan Tzatzkin Wix provides cautious 2025 guidance after strong 2024

The Israeli website building platform company reported its first-ever GAAP operating profit in 2024.

Saar Yoskovitz and Gal Shaul  / Photo: Augury Israeli industrial AI co Augury raises $75m

The new round represents an increase in valuation for Augury, which maintains its position as a ‘unicorn’ startup.

Eitan Yochananof and Eyal Ravid credit: Eyal Izhar and Tali Bogdanovsky Regulator indicts Victory, Yochananof CEOs over price fixing

The Israel Competition Authority today issued first indictments, following the food price fixing investigation.

Shekel credit: Shutterstock Vladirina 32 Shekel gains continue as Gaza talks progress

The shekel continues to trade at its strongest levels against the dollar since early 2023.

New York credit: Shutterstock Tel Aviv - New York fares stay high despite US airlines return

Ticket prices to the US will continue to cost at least $1,200 return, according to Ophir Tours, with most fares ranging between $1,500 and $2,000, or even more.

Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018